ENGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
enGene Therapeutics Inc (ENGN) is not a strong buy for a beginner, long-term investor at this time. While the stock has some positive analyst ratings and potential catalysts in the pipeline, the technical indicators suggest overbought conditions, and the financial performance shows significant losses. The options data also indicates bearish sentiment. Given the user's preference for long-term investment and the lack of immediate strong buy signals, holding off on this stock for now is advisable.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 82.071, signaling overbought conditions. The stock is trading near resistance levels (R1: 7.976, R2: 8.358), suggesting limited upside potential in the short term.
Analyst ratings from firms like WBB Securities, Jefferies, and Guggenheim are positive, with price targets significantly above the current price. The upcoming LEGEND trial updates and potential BLA submission in 2026 could serve as long-term catalysts.
The stock is overbought based on RSI, and the financials show significant losses with no revenue growth. Options data indicates bearish sentiment, and there is no recent news or congress trading data to suggest immediate positive momentum.
In Q1 2026, the company reported a net income loss of -$29.75M, though this is a 20.86% improvement YoY. EPS dropped to -0.44, down 8.33% YoY, and revenue remains at 0 with no growth. The financials indicate a company still in a developmental phase with high expenses.
Analyst ratings are mixed but lean positive. WBB Securities initiated coverage with a Buy rating and a $21.50 price target. Jefferies and Guggenheim also maintain Buy ratings with price targets of $28 and $27, respectively. However, UBS and Oppenheimer have lowered price targets due to increased spending and delayed catalysts.
